Recently, Selepump® Inflation Device, developed by Kossel Medtech (Suzhou) Co., Ltd., has successfully obtained market approval from the Singapore Health Sciences Authority (HSA), officially gaining access to the Singapore market.

With this latest approval, the product now holds three internationally recognized certifications—EU CE 2797, U.S. FDA clearance, and Singapore HSA registration—further expanding its global market access.
As an accessory device for percutaneous coronary intervention (PCI) procedures, the Selepump® Inflation Device features a high-precision pressure gauge and a safety locking mechanism, providing stable inflation and controlled, safe deflation. Its ergonomically designed handle ensures comfortable operation during prolonged procedures, while multiple model options are available to meet the needs of a wide range of vascular interventional procedures, combining safety with ease of use.
Singapore is a leading medical hub in Southeast Asia, renowned for its advanced healthcare system and stringent regulatory standards for medical devices. This approval not only demonstrates the recognition of Chinese-made interventional medical devices in Southeast Asia’s premium healthcare market, but also lays a solid regulatory foundation for Kossel Medtech (Suzhou) Co., Ltd. to further strengthen its presence across the region.
Guided by its “Local Base, Global Reach” globalization strategy, Kossel Medtech (Suzhou) Co., Ltd. has obtained more than 20 overseas registrations for its portfolio of interventional products, covering markets across Asia, Europe, the Americas, and the Middle East. Looking ahead, the company will continue to deliver high-quality vascular interventional devices to healthcare professionals worldwide, bringing the benefits of innovative medical technology to patients around the globe.